Hepion Pharmaceuticals, Inc. Profile Avatar - Palmy Investing

Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2…

Biotechnology
US, Edison [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Hepion Pharmaceuticals, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of HEPA's Analysis
CIK: 1583771 CUSIP: 426897104 ISIN: US4268973025 LEI: - UEI: -
Secondary Listings
HEPA has no secondary listings inside our databases.